FSC Laboratories, Inc. to Market AcipHex® Sprinkle™ (rabeprazole sodium) in the U.S.

  FSC Laboratories, Inc. to Market AcipHex® Sprinkle™ (rabeprazole sodium) in
  the U.S.

Business Wire

CHARLOTTE, N.C. -- June 30, 2014

FSC Therapeutics, LLC, today announced that the Company has entered into a
transaction with Eisai Inc. to acquire exclusive U.S. marketing rights for
AcipHex® Sprinkle™ (rabeprazole sodium), Delayed-Release Capsules, 5 mg and 10
mg, for the treatment of Gastroesophageal Reflux Disease (GERD) in children 1
to 11 years of age for up to 12 weeks. AcipHex Sprinkle will be distributed by
FSC Laboratories, Inc., and promoted by its subsidiary, FSC Pediatrics, Inc.,
to pediatric primary care-focused practitioners across the U.S.

“The addition of AcipHex Sprinkle to our portfolio of products demonstrates
our commitment to improving the health of pediatric patients. We are pleased
to offer a treatment option for the many young children who suffer from GERD,”
said Peter W. Steelman, President and Chief Executive Officer of FSC

AcipHex Sprinkle is a delayed-release capsule that can be sprinkled on a small
amount of soft food (e.g., applesauce, fruit or vegetable based baby food, or
yogurt) or the capsule granules can be emptied into a small amount of liquid
(e.g., infant formula, apple juice, or pediatric electrolyte solution).

The approval of AcipHex Sprinkle is supported by the largest clinical study
conducted in pediatric patients 1 to 11 years of age for the treatment of
GERD. The clinical trial was a multicenter, double-blind, parallel-group study
conducted in 127 pediatric patients over a 12-week treatment period and a
24-week extension period of two dose levels of rabeprazole. The AcipHex
Sprinkle study enrolled children with endoscopically confirmed GERD who were
reevaluated endoscopically at the conclusion of the study.

Overall, 81 percent of patients achieved healing during the 12-week treatment
period and 90 percent of those patients retained healing during the ensuing
24-week extension period. The absence of a placebo group does not allow
assessment of sustained efficacy through 36 weeks. There were no adverse
reactions reported in this study that were not previously observed in
adolescents or adults.

About AcipHex® Sprinkle™

Indication for AcipHex Sprinkle

AcipHex Sprinkle is indicated for the treatment of GERD in children 1 to 11
years of age for up to 12 weeks.

Important Safety Information about AcipHex Sprinkle:

  *Symptom relief does not rule out other serious stomach conditions.
  *Serious allergic reactions may occur. Tell your doctor if you have a rash,
    face swelling, throat tightness, or difficulty breathing.
  *Proton Pump Inhibitor (PPI) medicines may increase your risk of getting
    severe diarrhea. This diarrhea may be caused by an infection (Clostridium
    difficile) in your intestines. If you have watery stool, stomach pain, and
    fever that does not go away, call your doctor immediately.
  *People who are taking multiple daily doses of PPI medicines for a long
    period of time may have an increased risk of fractures of the hip, wrist,
    or spine.
  *Low magnesium can happen in some people who take a PPI medicine for at
    least 3 months. Tell your doctor right away if you experience any of these
    symptoms: seizures, dizziness, abnormal or fast heartbeat, jitteriness,
    jerking movements or shaking (tremors), muscle weakness, spasms of the
    hands and feet, cramps or muscle aches, or spasm of the voice box.
  *In children 1-11 years of age, the most common side effects with AcipHex
    include abdominal pain, diarrhea and headache.
  *Before taking AcipHex, tell your doctor if you are taking any of these
    medicines: atazanavir, digoxin, iron salts, ketoconazole, warfarin, or

For more information about AcipHex Sprinkle (rabeprazole sodium), click here
for the full Prescribing Information or visit www.aciphex.com.

ACIPHEX® Sprinkle™ is a trademark of Eisai R&D Management Co., Ltd.

About FSC Pediatrics

FSC Pediatrics, Inc., a subsidiary of FSC Laboratories, based in Charlotte,
NC, is a specialty pharmaceutical and medical device company founded in 2004,
solely dedicated to providing innovative solutions to unmet medical needs for
pediatric patients. FSC Pediatrics provides products that meet pediatric
primary care and specialist needs in the following therapeutic categories:
Infection, Central Nervous System (CNS), and Allergy/Asthma. More information
is available at www.fscpediatrics.com.


FSC Pediatrics
Paul Feirstein, 704-941-2500
Vice President Marketing and Sales
Press spacebar to pause and continue. Press esc to stop.